Sarcoptes scabiei is a causative organism for scabies that affects an estimated global population of 300 million and remains a disease of significant concern. Recently, a number of potential drug targets were identified for scabies, including hydrolytic enzymes, inactivated paralogues of hydrolytic enzymes, inhibitors of host proteolytic enzymes and other proteins of interest. These discoveries remain confined to academic laboratories and institutions, failing to attract interest from researchers in commercial drug development. Here, we summarize the latest developments in the scabies mite biology and the drug targets that were subsequently identified, and we propose several peptide and nonpeptide ligands targeting the hot spots for protein?protein interactions. We also identify gaps in the development of ligands as inhibitors or modulators of these macromolecules.
|Julkaisu||Future Medicinal Chemistry|
|DOI - pysyväislinkit|
|Tila||Julkaistu - 27 marrask. 2020|
|OKM-julkaisutyyppi||A2 Arvio tiedejulkaisuussa (artikkeli)|